Franco Nolè

European Institute of Oncology — Italy

Medicine · Health Sciences

49h-index13.4kcitations297works17.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(63), Renal cell carcinoma treatment(55), Breast Cancer Treatment Studies(49), Cancer Genomics and Diagnostics(45), HER2/EGFR in Cancer Research(41)

Publications296 total

Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 study
Frontiers in Oncology·2026Open Access
First-Line Therapy For Advanced Non–Clear Cell Renal Cell Carcinoma
JAMA Oncology·2025· 7 citedOpen Access
Retroperitoneal lymph node dissection for testis cancer: a comparison between open and robot-assisted approach in oncological and surgical outcomes
European Journal of Surgical Oncology·2025· 2 cited
Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial
Annals of Oncology·2025· 24 citedOpen Access
PSA and alkaline phosphatase changes in the EORTC-1333 PEACE-3 study evaluating the addition of six cycles of radium 223 in metastatic castration-resistant prostate cancer (mCRPC) starting enzalutamide.
Journal of Clinical Oncology·2025· 1 cited
Advancing breast cancer therapy in the era of molecular diagnostics
The Breast·2025· 5 citedOpen Access
MP16-07 RUCAPARIB VS DOCETAXEL OR SECOND-GENERATION ANDROGEN RECEPTOR PATHWAY INHIBITOR THERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH <i>BRCA</i> MUTATIONS WITH OR WITHOUT LIVER METASTASES IN TRITON3
The Journal of Urology·2025
Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety.
Journal of Clinical Oncology·2025· 4 cited
Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis
European Urology·2025· 21 citedOpen Access
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial
Annals of Oncology·2024· 37 citedOpen Access
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study
Clinical Genitourinary Cancer·2024· 3 cited
LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3
Annals of Oncology·2024· 33 citedOpen Access
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab
Immunotherapy·2024· 1 citedOpen Access
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study
Frontiers in Immunology·2024· 9 citedOpen Access
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study
Cancer Immunology Immunotherapy·2024Open Access
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
The Lancet Oncology·2024· 175 citedOpen Access
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of Meet-URO15 study
Research Square (Research Square)·2024Open Access
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study
Frontiers in Oncology·2024· 3 citedOpen Access
Phase II study of axitinib intensification compared to nivolumab alone after induction with ipilimumab plus nivolumab in patients with mRCC without previous complete response (AxIn study).
Journal of Clinical Oncology·2024
Multiomics approach for patient stratification and novel target identification in metastatic clear cell renal carcinoma (Meet-URO 31).
Journal of Clinical Oncology·2024· 1 cited
page 1 of 15Next →

Frequent Co-authors

Giuseppe Curigliano(14), Aron Goldhirsch(14), Elisabetta Munzone(13), Giuseppe Viale(13), Nicole Rotmensz(10), Marco Colleoni(9), Aron Goldhirsch(9), Paolo Veronesi(8), Giuseppe Renne(8), Laura Adamoli(8), Maria Teresa Sandri(7), Vincenzo Bagnardi(7), Laura Zorzino(6), Viviana Galimberti(6), Mattia Intra(6), Alberto Luini(6), Roberto Orecchia(6), Elena Verri(6), Giancarlo Pruneri(5), Stefano Zurrida(5)